Views & Analysis Digital health round-up: can Xcertia clear the health app co... A round-up of this week’s top digital healthcare news. Marco Ricci reports.
Novartis Strong phase 3 data boosts Novartis' Ibrance rival Ribociclib will compete against Pfizer's breast cancer blockbuster
News Pfizer fined £84m for exploiting epilepsy drug price Pfizer hiked price by 2600%, says competition watchdog.
News BeyondSpring plans three-pronged attack on cancer The CEO of BeyondSpring said the company hopes to make its name with a new lung cancer drug and an innovative R&D strategy.
News Pfizer looks to confirm US licence for breast cancer pill Pfizer has filed late stage data with FDA.
News NICE recommends Afinitor, Xalkori, as cancer drug review con... NICE has recommended two cancer drugs, as it continues its review of treatments in the old Cancer Drugs Fund.
News Pulmonary fibrosis drug developer Avalyn files IPO Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
